Global Nuclear Medicine Market Size, Trend & Opportunity Analysis Report, by Product (Diagnostics, Therapeutics), Application (Cardiology, Neurology, Oncology), End Use (Hospitals, Diagnostic Centres), and Forecast, 2025–2035

Market Definition and Introduction
The global nuclear medicine market was valued at USD 17.77 billion in 2024 and is projected to reach USD 532.99 billion by 2035, at a very high CAGR of 10.5% during the forecast period of 2025-2035. Nuclear medicine has become a disruptive technology with stronger acceptance since the medical community has begun to favour precise, personalised, and minimally invasive options for diagnosis and management. It provides an interface between molecular biology and radiology to realise specific imaging and radiopharmaceutical therapies, giving insight into the physiological functions at cellular and molecular levels like no other.
Market has matured, moving from the conventional definitions to a paradigm shift, fuelled by technology innovations, increasing clinical indications, and an ageing population suffering from ever-increasing chronic diseases. Nuclear medicine diagnostics, especially PET and SPECT, are revolutionising early-stage diagnosis in cardiology, oncology, and neurology. These modalities are clinically useful for functional imaging, overcoming the evident shortcomings of anatomical scans, thus allowing the physician to map treatment with very high precision. The other side of the story includes how therapeutic applications, such as radioligand therapy for metastatic cancers, are reshaping the management of advanced diseases.
Increasing recognition of nuclear medicine as the answer to low-cost, non-invasive, but highly accurate diagnostics is forcing the hands of healthcare institutions, research organisations, and governments alike to bring more into nuclear medicine. Ongoing innovations in radiopharmaceuticals, increasing access to isotopes, and enhancing cyclotron and generator technologies are pulling the ecosystem. Nuclear medicine has the potential to rewrite the clinical playbook in the coming years, from fast-tracking cancer diagnosis to ushering breakthroughs in Alzheimer's and cardiac disease.

Recent Developments in the Industry

In April 2024, Telix Pharmaceuticals announced the commercial launch of its prostate cancer imaging agent, Illuccix®, across multiple EU markets, strengthening its position in the diagnostics landscape with Gallium-68-based PET imaging agents.
In October 2023, Siemens Healthineers partnered with the University of California to develop AI-driven SPECT imaging algorithms aimed at enhancing the accuracy and speed of neurological and cardiovascular scans, indicating a major move toward precision diagnostics.
In June 2023, Jubilant Radiopharma expanded its theranostics pipeline through the acquisition of a Canadian radiopharmaceutical development firm. The acquisition supports its ambition to broaden access to novel radioligand therapies in North America and Europe.

Market Dynamics

Increasing Demand for Speedy and Accurate Detection of Illnesses by the Functional Imaging Modalities
There is a burgeoning demand for diagnostic tests aimed at finding bona fide physiological changes at the level of the molecules. With its SPECT and PET studies, nuclear medicine imaging strategies provide the highest functional data useful for early diagnosis, especially for malignancies, for neurodegenerative disorders like Alzheimer's, and for the cardiovascular system. This accelerating demand for nuclear diagnostics is gaining acceptance, especially in primary and tertiary care centres, as clinicians seek modalities that go beyond structural evaluation.
Novel Oncology Therapeutic Models Are Boosting the Growth of Radiopharmaceutical Therapeutics
Of late, rapid changes have been brought in nuclear medicine by its treatment aspect, especially in oncology, where targeted radioligand therapies are currently being used to treat prostate, neuroendocrine, and thyroid cancers. The treatments deliver cytotoxic radiation selectively to cancer cells while sparing the innocent, healthy tissue. The demand for therapeutic nuclear medicine should see exponential growth as drug developers continue to combine nuclear agents with antibody or peptide vectors.
Global Shortage of Isotopes and Limited Infrastructure Challenge Market Expansion
Despite promising growth opportunities, the nuclear medicine sector operates under a constraint of supply chain vulnerabilities, with radioisotope availability as a key factor. The ageing of reactors with limited cyclotron infrastructure in many regions purposely creates a bottleneck in the production of isotopes, thereby jeopardising the timely availability of diagnostics and therapeutics. Furthermore, the high costs associated with radio pharmacy infrastructure and skilled workforce availability continue to hinder its adoption, especially in developing economies.
Rise of Personalized Medicine and Companion Diagnostics Catalyzes Market Opportunities
The future of nuclear imaging and theranostics is intricately linked to the development of precision medicine. Physicians depend on radiolabelled biomarkers to guide patient-specific treatment pathways, particularly for cancers with high heterogeneity. Consequently, the increasing role of nuclear medicine in monitoring treatment response and in stratifying patient populations inspires new clinical pathways that enhance cost-effectiveness and therapeutic outcomes.
Digitalisation and AI Are Reshaping the Nuclear Imaging Ecosystem
AI adoption within nuclear medicine imaging platforms is boosting diagnostic accuracy, optimising image reconstruction, and addressing interpretative delays. AI-enabled tools are revolutionising radiation dose planning, workflow efficiencies of radio pharmacies, and predictive analytics for clinical decision refinement. These advancements are placing nuclear medicine at the confluence of digital health and therapeutic innovation.

Attractive Opportunities in the Market

Theragnostic Revolution – Combining diagnosis and treatment drives personalised radiopharmaceutical innovation
Growing Oncology Applications – Targeted radiotherapy gains traction in solid tumour management
AI in Imaging – Automation accelerates diagnostic precision and interpretation
Proliferation of Cyclotrons – Local radioisotope production improves accessibility and cost control
Hospital Radio pharmacies – On-site formulation boosts therapy turnaround
Neuroimaging Demand – Alzheimer’s and epilepsy fuel uptake of brain-specific tracers
Collaborative Clinical Trials – Pharma-radiology partnerships expedite drug-radioisotope synergies
Regulatory Streamlining – Accelerated approvals for diagnostics and therapeutic agents encourage market entry

Report Segmentation

By Product:

Diagnostics
SPECT (TC-99m, TL-201, GA-67, I-123, Others)
PET (F-18, SR-82/RB-82, PYLARIFY, Illuccix, Others)
Therapeutics
Alpha Emitters (RA-223, Others)
Beta Emitters (I-131, Y-90, SM-153, Re-186, Lu-177, Others)
Brachytherapy (Cesium-131, Iodine-125, Palladium-103, Iridium-192, Others)
By Application:

Cardiology (SPECT, PET, Therapeutic Applications)
Neurology
Oncology
Thyroid (SPECT, Therapeutic Applications)
Lymphoma
Bone Metastasis (SPECT, Therapeutic Applications)
Endocrine Tumour
Pulmonary Scans
Urology
Others
By End Use: Hospitals, Diagnostic Centres
By Region: North America (U.S., Canada, Mexico), Europe (UK, Germany, France, Spain, Italy, Spain, Rest of Europe), Asia-Pacific (China, India, Japan, Australia, South Korea, Rest of Asia-Pacific), LAMEA (Brazil, Argentina, UAE, Saudi Arabia (KSA), Africa Rest of Latin America)
The key players: Siemens Healthineers, GE HealthCare, Cardinal Health, Bracco Imaging, Curium Pharma, Jubilant Radiopharma, Lantheus Holdings, Telix Pharmaceuticals, Advanced Accelerator Applications (Novartis AG), and Eckert & Ziegler.

Report Aspects

Base Year: 2024
Historic Years: 2022, 2023, 2024
Forecast Period: 2025-2035
Report Pages: 293

Dominating Segments

Product Segment: Therapeutics: Give evidence of Reaching Heights in the Management of Cancer and Rare Disease
There is a spurt in therapeutic nuclear medicine because of the applications in targeted cancer therapy and other chronic diseases. Radioligand therapy with isotopes such as Lutetium-177 and Actinium-225 is changing the landscape of therapy in the metastatic setting. These precision therapies give localised radiation to tumour cells as opposed to the conventional chemotherapy process and improve the quality of life of patients.
Application Segment: Oncology Has the Largest Market Share Owing to Advances in Radiopharmaceuticals
Oncology continues to hold the largest application area in nuclear medicine because highly precise and functional imaging tools are required to diagnose and monitor cancer treatment. The making of tumour-targeting radiotracers specific to prostate and neuroendocrine cancers continues to drive strong adoption. The nuclear imaging contribution to treatment planning and follow-up continues to be a major part of contemporary care pathways for cancer.
Application Segment: Cardiology and Neurology Also Witnesses Substantial Expansion
Nuclear medicine plays a significant role in the evaluation of myocardial perfusion and viability in the setting of ischemic heart disease. In neurology, the major applications of PET imaging include the Department of Health and Human Services' Alzheimer's disease, Parkinson's disease, and epilepsy. The growing ageing population and increasing rates of neurological disease continue to drive growth within this segment.
End Use Segment: Hospitals Dominate While Diagnostic Centers Are Fast Emerging as Specialized Hubs
Hospitals are the largest end users of nuclear medicine procedures today due to their different infrastructure, provision of multidisciplinary expertise, and capacity to perform both diagnostics and treatments. However, specialised diagnostic centres are fast gaining a foothold in the market by offering PET/CT and SPECT/CT inpatient services, giving faster access and relieving pressure on the hospital systems.

Key Takeaways

Diagnostics Segment Leads – PET and SPECT dominate for early disease detection and monitoring
Therapeutics Segment Rising – Radioligand therapy reshapes oncology and rare disease treatment
Oncology Dominates – Nuclear imaging is critical to diagnosis, staging, and therapeutic response
Hospitals as Core Users – Integrated infrastructure supports diagnostics and therapies
AI and Digital Imaging – Smart platforms optimise analysis, accuracy, and turnaround time
Isotope Supply Chain Critical – Cyclotron expansion improves regional availability
Personalised Medicine Drives – Targeted diagnostics enhance patient stratification
Radio pharmacy Integration – On-site formulation improves logistics and safety compliance
Neuroimaging Growth – Rising Alzheimer’s cases accelerate demand for brain scans
Asia-Pacific Market Potential – Increasing investments in nuclear healthcare infrastructure

Regional Insights

Robust R&D, Along with Healthcare Infrastructure, Accounted for the Market Leadership of North America
Factors such as high per capita spending on healthcare, increasing acceptance of precision diagnostics, and advanced radio pharmacy infrastructure have made North America lead the global nuclear medicine market. The U.S. has a significant share in global PET and SPECT procedures and continues to be one of the hottest locations for conducting clinical trials with radiopharmaceuticals in the field of oncology and neurology.
Europe Fosters Innovation with Public-Private Collaboration and Reimbursement Support
The 2nd largest share belongs to Europe, where well-structured healthcare systems in Germany, France, and the UK spearhead the implementation of nuclear medicine. Public healthcare support, strong academic-industrial collaborations, and increasing numbers of research and development initiatives in radiopharmaceuticals create fertile ground for both diagnostic and therapeutic nuclear applications across the region.
Asia-Pacific Emerges as the Fastest-Growing Market with Escalating Chronic Disease Burden
In terms of market growth, Asia-Pacific is expected to register the highest CAGR during the period of forecast period. Increasing cancer rates, improving medical imaging infrastructure, and rising investments in isotope production propel nuclear medicine acceptance in the region. Nuclear diagnostics are under strong focus in countries such as India, China, and Japan, being conducted in a larger sense of healthcare modernisation.
LAMEA Regions Gradually Embracing Nuclear Medicine through Targeted Investments in Healthcare
Latin America and the Middle East & and Africa have slowly begun implementing nuclear medicine services into the framework of national cancer control and diagnostic imaging programs. Brazil and Saudi Arabia have been noticeably active in trying to increase their isotope production capacity and their radiology services, while multinational companies are partnering strategically to hasten access and build local capacity.

Core Strategic Questions Answered in This Report

Q. What is the expected growth trajectory of the nuclear medicine market from 2024 to 2035?
The global nuclear medicine market is projected to grow from USD 17.77 billion in 2024 to USD 532.99 billion by 2035, reflecting a CAGR of 10.5% over the forecast period (2025–2035). This expansion is primarily driven by the increasing adoption of radiopharmaceuticals for diagnostics and therapeutic purposes across oncology, cardiology, and neurology.
Q. Which key factors are fuelling the growth of the nuclear medicine market?

Several key factors are propelling market growth:

Surging demand for accurate, non-invasive diagnostics in cancer and cardiac care
Increasing use of radioligand therapy for targeted cancer treatment
Growing investment in radiopharmaceutical development and isotope production
AI and digital transformation of nuclear imaging platforms
Government healthcare modernisation initiatives and rising public-private partnerships
Q. What are the primary challenges hindering the growth of the nuclear medicine market?

Major challenges include:

High production costs and limited half-life of isotopes
Shortages in technetium-99m and other essential isotopes
Need for specialised infrastructure and trained personnel
Regulatory complexity surrounding radiopharmaceutical approval and use
Operational inefficiencies in radio pharmacy logistics and safety standards
Q. Which regions currently lead the nuclear medicine market in terms of market share?
North America leads the market due to its advanced healthcare infrastructure, high procedure volumes, and radiopharmaceutical R&D activity. Europe follows with strong regulatory support and innovation, while Asia-Pacific is the fastest-growing region, driven by rising disease prevalence and healthcare investments.
Q. What emerging opportunities are anticipated in the nuclear medicine market?

The market is ripe with new opportunities, including:

Expansion of PET tracers and AI-powered diagnostic platforms
Theragnostic approaches in prostate, thyroid, and neuroendocrine cancers
Decentralised radio pharmacies for improved access
Strategic licensing and acquisition models for radiopharmaceutical IP
Clinical trial collaborations to accelerate next-gen radiotherapeutics

Key Benefits for Stakeholders

The report offers a quantitative assessment of market segments, emerging trends, projections, and market dynamics for the period 2024 to 2035.
The report presents comprehensive market research, including insights into key growth drivers, challenges, and potential opportunities.
Porter's Five Forces analysis evaluates the influence of buyers and suppliers, helping stakeholders make strategic, profit-driven decisions and strengthen their supplier-buyer relationships.
A detailed examination of market segmentation helps identify existing and emerging opportunities.
Key countries within each region are analysed based on their revenue contributions to the overall market.
The positioning of market players enables effective benchmarking and provides clarity on their current standing within the industry.
The report covers regional and global market trends, major players, key segments, application areas, and strategies for market expansion. Show more